As of Q4'25 (ending 2025-12-31), Pfizer's latest reported EPS stands at -0.29 USD, reflecting a return to negative earnings after several quarters of modest profitability. The corresponding year-over-year EPS growth rate for this quarter is -514.29%, indicating a significant decline compared to the same period last year. Looking at the period from Q1'23 to Q4'25, the EPS trend has been volatile, with notable swings between positive and negative values. After a sharp drop from 0.98 USD in Q1'23 to -0.59 USD in Q4'23, the company saw a partial recovery in 2024, peaking at 0.79 USD in Q3'24. However, this improvement was not sustained, as EPS declined again in subsequent quarters, culminating in another negative result in Q4'25. The YoY EPS growth line mirrors this volatility, with extreme negative growth in late 2023, a brief surge to 2.88 (288%) in Q3'24 and an outlier spike of 50 (5,000%) in Q2'25, before plunging to -5.14 (-514%) in Q4'25, highlighting ongoing earnings instability throughout the observed period.